Overview
Sunshine is a diversified Sri Lankan group spanning healthcare, consumer brands and agribusiness. The September quarter brought much faster sales and profit growth, but its gross and operating margins remained weak against comparable September periods, leaving stronger earnings and demanding valuation evidence in tension.
Price performance
At LKR 31.30 on 11 November 2026, SUN had risen 11.4% over one month, ahead of the ASPI over the same period. It sat 35.0% of the way from its 52-week low to high, while both recent volatility and trading volume were below the company's own recent norms.
The three-year record shows two falls of 15% or more, the deepest 31%, which has not yet recovered. Median daily turnover was LKR 7.2 million, and a LKR 1 million order is about 14% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
The shares trade at 20.2 times earnings, meaning LKR 20.20 is paid for every LKR 1 of the last twelve months' profit, and at 3.01 times book value, or just over LKR 3 for each LKR 1 of net assets. Those multiples sit at the 75th percentile for P/E and 90th percentile for P/B among diversified-holdings peers, so SUN is priced above much of its sector despite a 15.3% audited return on equity.
The own-record comparison is more demanding: the shares were more expensive than at all 14 recorded year-ends. A buyer at this price is relying materially on the September result, which supplied 41.9% of trailing EPS; at the year-ago net margin, the same price would represent 22.6 times earnings rather than 20.2 times.
The 7.3% dividend yield is the highest among the 17 sector peers with yields. Dividends rose to LKR 1.80 in FY2026 from LKR 0.98 in FY2025, while FY2027 has so far recorded a LKR 0.50 first interim payment and remains incomplete.
News and sentiment
Company coverage was unusually heavy, with 11 articles in the past 30 days against a normal monthly baseline of 4.2. Across 90 days, 11 of 17 material articles were positive, three negative and three neutral.
Results reported on 2 November put first-half FY2027 revenue at LKR 40.2 billion, up 24.4%, and profit after tax at LKR 3.7 billion, up 44.3%. The same coverage reported a 50:50 Zydus joint venture for a pharmaceutical plant with investment above USD 20 million, but gave no revenue or profit contribution to size its eventual earnings effect. Sunshine Healthcare also acquired a 21.92% stake in Doc990 for LKR 410.8 million, extending its exposure to digital health through an associate investment.
Financials
September-quarter revenue rose 32.0% year-on-year to LKR 21.6 billion, while operating profit grew 27.5% and net profit rose 76.6% to LKR 2.3 billion. Profit therefore grew faster than the operating result, aided by a lower below-the-line drag of LKR 1.3 billion versus LKR 1.5 billion a year earlier; finance costs, tax and other non-operating items still absorbed a substantial part of operating profit.
Gross margin was 29.1% versus 32.1% a year earlier, operating margin 16.8% versus 17.4%, and net margin 10.8% versus 8.1%. September has been the strongest quarter for operating margin on average over the six complete years on record, yet this quarter's gross margin was the worst of seven comparable Septembers and operating margin ranked six of seven. The better net result did not come from a stronger operating margin.
Total equity rose to LKR 28.6 billion from LKR 27.3 billion a year earlier, and the share count was unchanged at 2.0 billion. Of the quarter's group net profit, LKR 880 million belonged to minority shareholders, so group profit and the EPS attributable to SUN shareholders are not the same pool of earnings.
Risks
The leading financial risk is that the dividend currently exceeds reported earnings. The trailing payout ratio was 148.4% and dividend cover was 0.67 times, meaning profits covered only about two-thirds of the distribution recorded over the period.
Debt was 47.8% of equity attributable to owners at the March 2026 year-end. Interest cover was 12.94 times, so operating profit covered the interest bill comfortably, but the current ratio of 1.73 times means the group depends on continued conversion of inventory and receivables into cash to meet its short-term obligations. Cash conversion was 0.84 times, indicating that not all operating profit arrived as cash in that year.
Healthcare accounted for 57% of reported segment revenue and has faced regulated pharmaceutical price pressure in company reporting. Consumer operations, representing 29% of segment revenue, operate against an inflationary backdrop that raises distribution costs and pressures household purchasing power; the data does not quantify the effect on Sunshine.
Outlook
As at 11 November 2026, the next scheduled evidence is the interim quarter to 31 December 2026, expected to be filed between 3 and 14 February 2027. It will show whether the strong first-half revenue growth and September profit acceleration extend beyond the quarter that supplied an unusually large share of trailing earnings.
The LKR 0.50 first interim dividend went ex on 10 November, so a buyer after that date does not receive it; payment is due on 30 November. The reported Zydus plant and Doc990 investment broaden healthcare activity, but the available information does not quantify their near-term profit contribution.